King/Mylan Merger Will Provide Critical Mass To Develop Palatin ED Agent
Executive Summary
Mylan's acquisition of King will provide the critical mass necessary to develop PT-141, a Phase II intranasal sexual dysfunction agent in-licensed from Palatin, King said